

Series HCT/AIEPI-1.I

# Respiratory Infections in Children



Yehuda Benguigui  
Francisco J. López Antuñaño  
Gabriel Schmunis  
João Yunes

Pan American Health Organization  
World Health Organization

# RESPIRATORY INFECTIONS IN CHILDREN

Yehuda Benguigui  
Francisco J. López Antuñaño  
Gabriel Schmunis  
João Yunes



Series HCT/AIEPI-1.1

Integrated Management of Childhood Illness  
Communicable Diseases Program  
Division of Disease Prevention and Control



**PAN AMERICAN HEALTH ORGANIZATION**  
Pan American Sanitary Bureau, Regional Office of the  
**WORLD HEALTH ORGANIZATION**

525 Twenty-Third Street, N.W. Washington, D.C. 20037, U.S.A.  
*February 1999*

Benguigui, Y, ed.

Respiratory infections in children / edited by Yehuda Benguigui, Francisco J. López Antuñaño, Gabriel Schmunis and João Yunes. — Washington, D.C.; PAHO, © 1999.

xxv, 453 p. — (PAHO. Series HCT/AIEPI-1.1)

ISBN 92 75 12206 7

I. Title. II. Benguigui, Yehuda, ed. III. López Antuñaño, Francisco J., ed. IV Schmunis, Gabriel, ed. V. Yunes, João, ed. VI. (Series)

1. INFECTIONS OF THE RESPIRATORY TRACT – children.

2. IMMUNIZATION. 3. PRIMARY HEALTH CARE.

4. INFANT HEALTH SERVICES.

NLM WS280

The Pan American Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. Applications and inquiries should be addressed to the Regional Advisor on Integrated Management of Childhood Illness, Program on Communicable Diseases, Division of Disease Prevention and Control, which will be glad to provide the latest information on any changes made to the text, plans for new editions, and reprints and translations already available.

Publications of the Pan American Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved.

The designation employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the Pan American Health Organization concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the Pan American Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

Series HCT/AIEPI-1.1 — 1.000



# CONTENTS

<b>Editorial Committee</b> .....	xv
<b>Acknowledgement</b> .....	xvi
<b>Authors</b> .....	xvii
<b>Prologue</b> .....	xxi
<b>Introduction</b> .....	xxii

## SECTION I: MAGNITUDE OF THE PROBLEM

<b>Chapter 1</b>	<b>Epidemiology of acute respiratory infections in children: regional overview</b> .....	<b>3</b>
	<i>F. J. López Antuñaño, M.D., M.P.H.</i>	
	I. Introduction .....	3
	II. Diagnosis .....	5
	III. Treatment .....	9
	IV. Incidence and prevalence .....	10
	V. Lethality and mortality .....	12
	VI. Nutrition and pneumonia .....	17
	VII. Conclusions. ....	17
	VIII. References .....	19
<b>Chapter 2</b>	<b>Magnitude and control of ARI in light of the goals of the world summit for children</b> .....	<b>23</b>
	<i>Dr. Yebuda Benguigui</i>	
	I. Introduction. ....	23
	II. Magnitude of the mortality for ARI in the Region of the Americas. .	24
	a) Official indicators .....	24
	b) Estimates .....	24

III. Pneumonia and influenza mortality trends . . . . .	28
IV. Importance of ARI as a cause of disease. . . . .	30
V. Community-based studies . . . . .	33
VI. Information from health service records . . . . .	33
VII. Prevalence of risk factors. . . . .	35
VIII. Perspectives on ARI control in countries of the Region. . . . .	38
IX. References . . . . .	39
<b>Chapter 3 Risk factors for acute lower respiratory infections . . . . .</b>	<b>41</b>
<i>César G. Victora, M.D., Ph.D.</i>	
I. Introduction . . . . .	41
II. Demographic risk factors. . . . .	42
a) Gender . . . . .	42
b) Age . . . . .	42
III. Socioeconomic risk factors. . . . .	42
a) Income . . . . .	42
b) Parental education . . . . .	42
c) Place of residence . . . . .	43
IV. Environmental risk factors . . . . .	43
a) Exposure to smoke . . . . .	43
b) Crowding . . . . .	45
c) Exposure to cold and humidity. . . . .	45
d) Exposure to other adverse environmental conditions. . . . .	46
V. Nutritional factors. . . . .	46
a) Low birth weight . . . . .	46
b) Malnutrition . . . . .	47
c) Lack of breast-feeding . . . . .	48
d) Vitamin A deficiency . . . . .	49
VI. Behavioral factors. . . . .	49
VII. Summary of risk factors and possible intervention. . . . .	50
Acknowledgments . . . . .	51
VIII. References . . . . .	51

<b>Chapter 4</b>	<b>Incidence and evolution of pneumonia in children at the community level</b> . . . . .	<b>59</b>
	<i>Claudio F. Lanata, M.D., M.P.H.</i>	
	I. Introduction . . . . .	59
	II. Definition of pneumonia or ALRI in community studies . . . . .	59
	III. Incidence of pneumonia or ALRI in community studies . . . . .	61
	a) In industrialized countries . . . . .	61
	b) In developing countries . . . . .	63
	IV. Epidemiological study in Lima, Peru . . . . .	67
	a) Description of the study and its methodology . . . . .	67
	b) Incidence of pneumonia . . . . .	68
	c) Natural history of pneumonia in the community . . . . .	69
	d) Duration of respiratory signs and symptoms . . . . .	73
	e) Prognosis for community pneumonia . . . . .	75
	V. Comments and conclusion . . . . .	78
	VI. References . . . . .	79

## **SECTION II: ETIOLOGICAL ASPECTS**

<b>Chapter 5</b>	<b>Viruses as the cause of upper and lower ARI in children: general characteristics and diagnosis</b> . . . . .	<b>87</b>
	<i>Professor Mercedes C. Weissenbacher and Doctor María M. Ávila</i>	
	I. Introduction . . . . .	87
	II. Diagnosis of viral ARI. . . . .	88
	a) Clinical specimens for diagnosis. . . . .	89
	b) Specimen processing. . . . .	89
	III. Respiratory syncytial virus (RSV). . . . .	92
	IV. Adenoviruses. . . . .	93
	V. Parainfluenza virus . . . . .	94
	VI. Influenza virus . . . . .	95
	VII. Rhinovirus. . . . .	97
	VIII. Coronaviruses . . . . .	97
	IX. Echovirus and coxsackievirus . . . . .	98
	X. References. . . . .	98
	XI. Appendices. . . . .	102

<b>Chapter 6</b>	<b>Characteristics of bacteria as etiological agents of acute respiratory infections in children: considerations for diagnosis</b>	<b>105</b>
	<i>Lúcia Martins Teixeira, Ph.D.</i>	
	I. Introduction . . . . .	105
	II. General observations on methods for obtaining specimens for laboratory diagnosis. . . . .	107
	III. <i>Bordetella pertussis</i> . . . . .	108
	IV. <i>Corynebacterium diphtheriae</i> . . . . .	109
	V. <i>Haemophilus influenzae</i> . . . . .	109
	VI. <i>Mycoplasma pneumoniae</i> . . . . .	110
	VII. <i>Streptococcus pneumoniae</i> . . . . .	111
	VIII. <i>Streptococcus pyogenes</i> . . . . .	113
	IX. Other bacterial causes of ARI. . . . .	114
	X. Final comments . . . . .	117
	XI. References . . . . .	117
<b>Chapter 7</b>	<b>New developments in pediatric bacterial vaccines</b>	<b>123</b>
	<i>Carl. E Frasch, Ph.D., Cbi-Jen Lee, D.Sc., Drusilla L. Burns, Ph.D.</i>	
	I. Introduction . . . . .	123
	II. <i>Haemophilus b</i> conjugate vaccines . . . . .	124
	III. Pneumococcal vaccines . . . . .	127
	IV. Pertussis vaccines . . . . .	129
	V. Other vaccines used in pediatric populations . . . . .	131
	VI. Conclusions . . . . .	132
	VII. References . . . . .	132
<b>Chapter 8</b>	<b>Production of vaccines for the prevention of ARI: a regional outlook</b>	<b>137</b>
	<i>Dr. Akira Homma, Dr. José Luis DiFabio, Dr. Ciro A. de Quadros</i>	
	I. Introduction . . . . .	137
	II. Vaccine research and technological development . . . . .	140
	III. Vaccine production. . . . .	147
	IV. Regional production . . . . .	148
	V. Conclusion . . . . .	151
	VI. References . . . . .	152

## SECTION III: CLINICAL ASPECTS AND TREATMENT

<b>Chapter 9</b>	<b>The common cold</b> . . . . .	159
	<i>Dr. Herminio R. Hernández Díaz</i>	
	I. Introduction . . . . .	159
	II. Etiology . . . . .	159
	III. Epidemiological aspects . . . . .	160
	IV. Pathogenesis . . . . .	162
	V. Clinical findings . . . . .	163
	VI. Complications . . . . .	164
	VII. Diagnosis and differential diagnosis . . . . .	164
	VIII. Treatment . . . . .	165
	IX. Prevention . . . . .	168
	X. Conclusion . . . . .	168
	XI. References . . . . .	169
<b>Chapter 10</b>	<b>Acute respiratory infections of the upper respiratory tract</b> . . .	173
	<i>Dr. Romeo S. Rodríguez</i>	
	I. Acute streptococcal pharyngotonsillitis . . . . .	173
	a) Clinical presentation . . . . .	173
	b) Diagnosis . . . . .	174
	c) Treatment . . . . .	176
	d) Nonstreptococcal pharyngitis . . . . .	179
	II. Acute otitis media . . . . .	180
	a) Definitions . . . . .	180
	b) Incidence and epidemiology . . . . .	180
	c) Risk factors . . . . .	181
	d) Pathogenesis . . . . .	181
	e) Clinical presentation . . . . .	181
	f) Specific otoscopic diagnosis . . . . .	183
	g) Etiology . . . . .	183
	h) Treatment . . . . .	184
	III. Acute sinusitis . . . . .	187
	a) Anatomopathology . . . . .	187
	b) Predisposing factors and classification . . . . .	187
	c) Clinical presentation . . . . .	188



	d) Specific diagnostic methods . . . . .	189
	e) Microbiology of sinusitis . . . . .	190
	f) Treatment . . . . .	191
	IV. Croup and other infectious obstructions of the upper respiratory tract. . . . .	192
	a) Definition of terms. . . . .	192
	b) Supraglottic obstruction (epiglottiditis) . . . . .	192
	c) Subglottic obstruction . . . . .	196
	V. References . . . . .	199
<b>Chapter 11</b>	<b>Viral and bacterial pneumonias</b> . . . . .	<b>205</b>
	<i>Dr. Raúl Ruvinski, Dra. María C. Balanzat</i>	
	I. General considerations . . . . .	205
	II. Etiology and pathogenesis . . . . .	206
	a) Pulmonary defense mechanisms . . . . .	206
	b) Bacterial mechanisms of action. . . . .	207
	III. Clinical evaluation . . . . .	208
	IV. Radiological evaluation . . . . .	217
	V. Laboratory data . . . . .	225
	VI. Treatment . . . . .	226
	VII. References . . . . .	231
<b>Chapter 12</b>	<b>Recurrent or chronic pneumonia: differential diagnosis and management</b> . . . . .	<b>239</b>
	<i>Dr. Gustavo Aristizábal Duque</i>	
	I. Introduction . . . . .	239
	II. Definition . . . . .	239
	III. Guidelines for differential diagnosis: Clinical presentation . . . . .	240
	IV. Etiology according to prevalence . . . . .	241
	V. Diagnostic and therapeutic guidelines . . . . .	241
	a) Sequelae of prior ARI . . . . .	241
	b) Aspiration pneumonias . . . . .	242
	c) Sequelae of respiratory disease in the newborn. . . . .	243
	d) Environmental contamination. . . . .	243
	e) Immunological changes. . . . .	244
	f) Cardiopathies. . . . .	244

g) Severe asthma . . . . .	244
h) Pulmonary tuberculosis . . . . .	245
i) Foreign body in the airways . . . . .	245
k) Bronchial anomalies and bronchial dyskinesia . . . . .	245
VI. Conclusion . . . . .	246
VII. References . . . . .	246
<b>Chapter 13 Bronchiolitis . . . . .</b>	<b>247</b>
<i>Dr. Clemax Couto Sant'Anna and Dr. Claudio D'Elia</i>	
I. Introduction . . . . .	247
II. Etiology . . . . .	248
III. Epidemiology . . . . .	248
IV. Pathogenesis . . . . .	249
V. Diagnosis . . . . .	251
a) Clinical and radiological diagnosis . . . . .	251
b) Laboratory diagnosis . . . . .	252
VI. Differential diagnosis . . . . .	253
VII. Treatment . . . . .	253
a) Bronchodilators . . . . .	254
b) Ribavirin . . . . .	255
VIII. Sequelae . . . . .	256
IX. Prevention . . . . .	257
Acknowledgments . . . . .	257
X. References . . . . .	258
<b>Chapter 14 Treating asthma in children . . . . .</b>	<b>265</b>
<i>Dr. María Eugenia Gama</i>	
I. Introduction . . . . .	265
II. Diagnosis . . . . .	266
a) Clinical findings . . . . .	266
b) Aspects of patient history that support diagnosis . . . . .	267
c) Functional diagnosis . . . . .	267
d) Importance and application of PEF measurements in treatment . . . . .	268
III. Treatment of asthma . . . . .	271
a) Objective . . . . .	271
b) General plan of treatment for asthma . . . . .	275
c) Considerations regarding drugs used to treat asthma . . . . .	276

d) Educating the patient and family . . . . .	285
IV. References . . . . .	287

**Chapter 15 Pneumonia in the immunocompromised and in the malnourished child . . . . . 289**  
*Dr. Renato Tetelbom Stein*

I. Introduction . . . . .	289
II. Lung defense mechanisms. . . . .	290
III. Pneumonia in malnourished children. . . . .	290
IV. Pneumonia in the immunosuppressed host . . . . .	291
V. Pneumocystis carinii pneumonia . . . . .	293
a) Physiopathology. . . . .	293
b) Clinical findings . . . . .	294
c) Diagnosis . . . . .	294
d) Treatment . . . . .	295
VI. Tuberculosis and HIV infection. . . . .	295
a) Pathogenesis . . . . .	295
b) Clinical findings . . . . .	296
c) Diagnosis . . . . .	296
d) Treatment . . . . .	297
VII. Lymphoid interstitial pneumonitis (LIP). . . . .	297
a) Physiopathology . . . . .	297
b) Clinical findings . . . . .	298
c) Diagnosis . . . . .	299
d) Treatment . . . . .	299
VIII. Toxoplasmosis. . . . .	299
a) Physiopathology . . . . .	299
b) Clinical findings . . . . .	300
c) Diagnosis . . . . .	300
d) Treatment . . . . .	300
IX. Viral pneumonia . . . . .	300
a) Giant cell pneumonia . . . . .	300
b) Cytomegalovirus (CMV) pneumonia . . . . .	301
c) Varicella-zoster virus pneumonitis . . . . .	302
d) Respiratory syncytial virus (RSV) . . . . .	303

X. Fungal pneumonias . . . . .	304
a) Pulmonary candidiasis . . . . .	304
b) Pulmonary aspergillosis . . . . .	305
XI. References. . . . .	307

## **SECTION IV: PREVENTION AND CONTROL**

<b>Chapter 16</b>	<b>Technical guidelines for the prevention, diagnosis, treatment, and control of ARI at the primary care level . . . . .</b>	<b>313</b>
	<i>Dr. Yebuda Benguigui</i>	

I. Introduction . . . . .	313
II. The toll of ARI among children. . . . .	313
III. Control measures . . . . .	316
IV. ARI control strategies . . . . .	316
V. Diagnostic criteria . . . . .	317
a) Entry criteria . . . . .	317
b) Identification of pneumonia cases. . . . .	318
c) Home care . . . . .	318
VI. Treatment. . . . .	318
VII. Importance of bacterial pneumonia . . . . .	320
VIII. Limitations of antibiotic treatment of ARIs . . . . .	321
IX. “Preventive” antibiotic treatment . . . . .	323
X. Use of cotrimoxazole in control activities . . . . .	324
XI. Integrated management of childhood illness (IMCI) . . . . .	326
a) Objectives of IMCI . . . . .	326
b) Rationale . . . . .	326
c) Conclusions and future prospects . . . . .	328
XII. References . . . . .	328

<b>Chapter 17</b>	<b>ARI in infants under 2 months of age . . . . .</b>	<b>331</b>
	<i>Dr. Gerardo Cabrera Meza</i>	

I. Epidemiology . . . . .	331
II. Etiology. . . . .	333
III. Diagnosis . . . . .	335
IV. Management . . . . .	337

	V. Preventive measures . . . . .	340
	VI. A glance at the future . . . . .	340
	VII. References . . . . .	340
<b>Chapter 18</b>	<b>Control of acute respiratory infections in children between 2 months and 5 years of age . . . . .</b>	<b>343</b>
	<i>Dr. Magnolia Arango Loboguerrero</i>	
	I. Overview . . . . .	343
	II. Etiology and physiopathogeny. . . . .	344
	III. Clinical manifestations . . . . .	345
	IV. Paraclinical diagnosis . . . . .	348
	V. ARI control . . . . .	349
	VI. What to avoid in ARI treatment . . . . .	353
	VII. References . . . . .	353
<b>Chapter 19</b>	<b>Results from ethnographic studies on the control of acute respiratory infections in Bolivia . . . . .</b>	<b>355</b>
	<i>Lic. María Dolores Charaly M.</i>	
	I. Introduction . . . . .	355
	II. Methodology . . . . .	356
	III. Study results. . . . .	356
	a) The Quwari community . . . . .	357
	b) Community of Jayuma Lallagua. . . . .	360
	IV. Use of ethnographic results . . . . .	364
	V. Conclusion . . . . .	365
	VI. References . . . . .	366
	VII. Appendices . . . . .	367
 <b>SECTION V: CONTROL OF ARI AT THE LOCAL LEVEL</b>		
<b>Chapter 20</b>	<b>Planning activities for control of ARI in the context of integrated care for children . . . . .</b>	<b>381</b>
	<i>Dr. Yebuda Benguigui</i>	
	I. Introduction . . . . .	381
	a) Mortality . . . . .	381

b) Morbidity . . . . .	382
c) Prevalence of risk factors. . . . .	383
d) The quality of case care. . . . .	383
II. The objectives and strategy of ARI control. . . . .	384
a) Standard case management . . . . .	384
b) Immunization against measles and whooping cough . . . . .	385
c) Reduction of risk factors . . . . .	386
III. Stages in the implementation of control activities . . . . .	386
IV. Steps to follow in implementation . . . . .	387
a) Description of the geographic area of implementation. . . . .	387
b) Up-to-date description of ARI situation in the area of implementation . . . . .	388
c) Establishment of the health network available for implementation	388
d) Planning implementation of ARI control activities . . . . .	389
V. Proposed goals and objectives for ARI control . . . . .	394
VI. Operational plans . . . . .	395
VII. References . . . . .	396
VIII. Appendices . . . . .	397

**Chapter 21 Evaluating control mechanisms for acute respiratory infections 417**  
*Dr. Jorge Toro Albornoz*

I. Introduction . . . . .	417
II. Control measures and evaluation structure . . . . .	418
III. Evaluation systems. . . . .	420
a) Periodic and systematized evaluation . . . . .	420
b) Sporadic evaluation . . . . .	421
IV. Qualitative evaluation . . . . .	425
V. Dissemination and feedback . . . . .	426
VI. References. . . . .	427

**Chapter 22 Indicators and parameters to assess activities at the local  
level to control acute respiratory infections 431**  
*Dr. Sergio J. Arias*

I. Introduction . . . . .	431
II. The assessment process . . . . .	432
a) Training . . . . .	432

b) Provision of supplies . . . . .	434
c) Supervision . . . . .	436
d) Access and use. . . . .	437
III. Assessment of impact. . . . .	439
a) Reductions in pneumonia mortality in children under 5. . . . .	440
b) Reduction in the excessive or inappropriate use of antibiotics and other ARI control drugs . . . . .	443
c) Reduction of complications from acute infections of the upper airways, especially hypoacusis and deafness secondary to otitis media . . . . .	444
IV. Presentation of the assessment and participation of health personnel in the processes of monitoring and assessment . . . . .	445
V. References . . . . .	446
VI. Appendices. . . . .	449